NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantumzyme's Next-Generation Enzyme Engineering Platform for Pharmaceutical Manufacturing
TL;DR
Quantumzyme's new enzymes give pharmaceutical manufacturers a cost advantage by reducing solvent usage and production cycles while maintaining quality.
Quantumzyme's enzyme platform uses AI modeling to enhance stability and selectivity, integrating with existing workflows to lower material and energy requirements.
Quantumzyme's technology supports sustainable manufacturing by enabling lower-impact solvents and reducing waste, making pharmaceutical production more environmentally responsible.
Quantumzyme applies quantum mechanics and AI to engineer enzymes that transform pharmaceutical manufacturing with greener, more efficient processes.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantumzyme is announcing a breakthrough advancement in its proprietary enzyme development platform, introducing a new generation of high-performance enzymes designed to improve efficiency across pharmaceutical manufacturing processes.
The newly developed enzymes demonstrate enhanced stability, selectivity, and compatibility with lower-cost extraction solvents like isopropyl alcohol as an alternative to commonly used solvents such as ethyl acetate.
Potential benefits include reduced solvent and material costs, improved reaction efficiency and conversion rates, lower energy and purification requirements, shorter production cycles, and enhanced scalability for commercial manufacturing.
The enzyme systems support more environmentally responsible manufacturing by enabling the use of lower-impact solvents, reducing waste generation, and lowering overall process energy requirements.
The technology is particularly relevant for high-volume active pharmaceutical ingredients (APIs) and complex chiral compounds, where solvent usage and purification steps account for a substantial portion of total manufacturing costs.
Quantumzyme's platform is designed for integration into existing production workflows, which may reduce the need for significant capital investment.
The enzyme development advancements are supported by the use of artificial intelligence and computational modeling tools designed to assist in enzyme analysis and optimization, including evaluating biochemical datasets and modeling structure-function relationships.
All enzyme candidates remain subject to laboratory validation, scale-up testing, and applicable regulatory considerations, despite the use of computational tools in development.
Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp., stated that these results mark an important step forward in modernizing pharmaceutical manufacturing through advanced enzyme engineering, with potential to deliver significant value across a range of pharmaceutical processes.
The announcement was made on January 27, 2026, from San Diego, CA.
Curated from NewMediaWire
